Therapeutic Consequences of 68Ga-PSMA-11-PET/CT in Prostate Cancer in Correlation to the Gleason Score, PSA Value, and D’Amico-Defined Risk Groups
Authors:
- Friederike EilsbergerFEFriederike Eilsberger
- Ali EbrahimifardAEAli Ebrahimifard
- Florian Torsten SpiegelFSFlorian Torsten Spiegel
- Behrooz Hooshyar YousefiBehrooz Hooshyar Yousefi
- Shamim BagheriSBShamim Bagheri
- Wadim BowlWBWadim Bowl
- Qi WangQWQi Wang
- Andreas PfestroffAPAndreas Pfestroff
- Laura MüllerLMLaura Müller
- Markus LusterMLMarkus Luster
- Pietro Di FazioPFPietro Di Fazio
- Damiano LibrizziDLDamiano Librizzi
Open Access
Abstract
Background/Objectives: The aim of this study was to demonstrate the importance of 68Gallium (68Ga)–prostate specific membrane antigen (PSMA)–positron emissions tomography (PET)/computed tomography (CT)(PET/CT) in prostate cancer patients for therapy management with individual analyses regarding the Gleason score, prostate specific antigen (PSA) value, and the risk groups defined by D’Amico. Methods: We retrospectively analyzed 562 68Ga-PSMA-11-PET/CT examinations performed from January 2015 to March 2023 at University Hospital Marburg. We assessed treatment changes post 68Ga-PSMA-11-PET/CT and categorized the cases based on PSA values, Gleason scores, and D’Amico risk groups. Results: In 415/562 (73.8%) of 68Ga-PSMA-11-PET/CT examinations, a modification in the therapy concept was recorded. Patients categorized as high risk or patients with Gleason scores of 7 through 10 or with PSA levels above 0.5 ng/mL (particularly within the ranges of 1.01–2 ng/mL, 3.01–5 ng/mL, and values exceeding 10 ng/mL) demonstrated a statistically significant association with treatment change. While no evidence of the disease was found most frequently in 38% of cases in the “Therapy continued without explicit reference” group, in the group with the adapted therapy, there was a considerable higher proportion of local tumors (19.2%) compared to the other groups (4.4% and 1.4%). Conclusions: Our results show the high impact of 68Ga-PSMA-PET/CT for patients with prostate cancer regarding therapy management planning, which is even more important for some patient groups.Keywords
Funding Information
- Clinician Scientist program of the Philipps University of Marburg
This publication has 36 references indexed in Scilit:
- PRIMARY scoring in 68Ga-PSMA PET/CT: correlation with prostate cancer risk groups and its potential impact on active surveillanceAnnals of Nuclear Medicine, 2024
- Evaluating response to radium-223 using 68Ga-PSMA PET/CT imaging in patients with metastatic castration-resistant prostate cancerAnnals of Nuclear Medicine, 2024
- EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2024
- Impact of PSMA PET on Prostate Cancer ManagementCurrent Treatment Options in Oncology, 2024
- Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy—a multi-centre evaluation of 2533 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology Focus, 2018
- Impact of 68 Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology, 2018
- 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2017
- 68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2015
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998